Patent no loss of MatrixView
Tuesday, 19 August, 2008
MatrixView [ASX: MVU] has been awarded a European Patent for its proprietary ABO technology.
The patent has been awarded for the company's proprietary Advanced Binary Optimisation (ABO) technology, which allows MatrixView's healthcare products to provide lossless data streams.
ABO is the backbone of MatrixView's healthcare products - such as its tele-radiology solution - where high-resolution, highly accurate data streams are required.
Its key feature is an ability to provide mathematically lossless data management – the ability to compress large amounts of data without losing any of that data, critical in medical applications.
The company has also applied for patents for ABO from the US.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
